Johnson & Johnson Innovative Medicine, has announced appointment of Camille Dorsey as Vice President, GI Sales & Marketing, taking on a broader leadership role within the company’s gastrointestinal (GI) business. Dorsey shared the news describing GI as an important part of her career and highlighting her continued focus on patients living with inflammatory bowel disease (IBD).
In her new position, Dorsey will bring together sales and marketing responsibilities across the GI organization. Her background includes leadership in immunology marketing and GI, with experience spanning healthcare professional and key opinion leader engagement, customer experience, market access, sales, and digital transformation. A professional profile also identifies her previous work as Director of Marketing for TREMFYA GI, where she was involved in the brand’s efforts in ulcerative colitis and Crohn’s disease.
Also Read: Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
The appointment comes as the GI and immunology landscape continues to evolve, with pharmaceutical companies focusing on differentiated treatments and broader approaches to managing complex immune-mediated conditions. Johnson & Johnson identifies immunology as one of its key therapeutic focus areas.
For Dorsey, the new role represents a continuation of her work in GI, while placing greater emphasis on connecting commercial strategy, field execution, and patient needs. She also highlighted the importance of the teams and colleagues who have shaped her career as she begins this next chapter.
